Pharmacological management of human respiratory syncytial virus infection

References

• Singanayagam A, Joshi P, Mallia P, et al. Viruses exacerbating chronic pulmonary disease: the role of immune modulation. BMC Med. 2012 Mar;10(1). DOI:10.1186/1741-7015-10-27.
   PubMed Web of Science ®Google Scholar
• Pickles RJ, DeVincenzo JP. Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis. J Pathol. 2015;235(2):266–276.
   PubMed Web of Science ®Google Scholar
• Calvo C, García-García ML, Blanco C, et al. Multiple simultaneous viral infections in infants with acute respiratory tract infections in Spain. J. Clin. Virol. 2008;42(3):268–272.
   PubMed Web of Science ®Google Scholar
• Obodai E, Odoom JK, Adiku T, et al. The significance of human respiratory syncytial virus (HRSV) in children from Ghana with acute lower respiratory tract infection: a molecular epidemiological analysis, 2006 and 2013-2014. PLoS One. 2018 Sep;13(9):e0203788.
   PubMed Web of Science ®Google Scholar
• Afonso CL, Amarasinghe GK, Bányai K, et al. Taxonomy of the order Mononegavirales: update 2016. Arch. Virol. 2016;161(8):2351–2360.
   PubMed Web of Science ®Google Scholar
• Bohmwald K, Gálvez NMS, Canedo-Marroquín G, et al. Contribution of cytokines to tissue damage during human respiratory syncytial virus infection. Front Immunol. 2019 Mar;10(MAR). DOI:10.3389/fimmu.2019.00452.
   PubMed Web of Science ®Google Scholar
• Collins PL, Fearns R, Graham BS. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol. 2013. DOI:10.1007/978-3-642-38919-1-1
   Web of Science ®Google Scholar
• Liuzzi M, Mason SW, Cartier M, et al. Inhibitors of respiratory syncytial virus replication target cotranscriptional mRNA guanylylation by viral RNA-dependent RNA polymerase. J. Virol. 2005;79(20):13105–13115.
   PubMed Web of Science ®Google Scholar
• Bermingham A, Collins PL. The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc Natl Acad Sci. 2002. DOI:10.1073/pnas.96.20.11259
   Web of Science ®Google Scholar
• Fearns R, Collins PL. Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription.. J Virol. 1999;73(7):5852–5864.
   PubMed Web of Science ®Google Scholar
• Lindquist ME, Mainou BA, Dermody TS, et al. Activation of protein kinase R is required for induction of stress granules by respiratory syncytial virus but dispensable for viral replication. Virology. 2011 Apr;413(1):103–110.
   PubMed Web of Science ®Google Scholar
• Jeffree CE, Rixon HWML, Brown G, et al. Distribution of the attachment (G) glycoprotein and GM1 within the envelope of mature respiratory syncytial virus filaments revealed using field emission scanning electron microscopy. Virology. 2003;306(2):254–267.
   PubMed Web of Science ®Google Scholar
• Hacking D, Hull J. Respiratory syncytial virus - viral biology and the host response. J Infect. 2002 Jul;45(1):18–24.
   PubMed Web of Science ®Google Scholar
• Schmidt A, Couch R, Galasso G, et al. Current research on respiratory viral infections: third International Symposium. Antiviral Res. 2001;50(3):157–196.
   PubMed Web of Science ®Google Scholar
• Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol. 2008;82(5):2040–2055.
   PubMed Web of Science ®Google Scholar
• Ruuskanen O, Ogra PL. Respiratory syncytial virus. Curr. Probl. Pediatr. 1993;23(2):50–79.
   PubMedGoogle Scholar
• Mastrangelo P, Hegele RG. RSV fusion: time for a new model. Viruses. 2013;5(3):873–885.
   PubMed Web of Science ®Google Scholar
• Radu G, Caidi H, Miao C, et al. Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in Respiratory Syncytial Virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice. J Virol. 2010 Sep;84(18):9632–9636.
   PubMed Web of Science ®Google Scholar
• Haynes LM, Caidi H, Radu GU, et al. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J Infect Dis. 2009;200(3):439–447.
   PubMed Web of Science ®Google Scholar
• Harcourt J, Alvarez R, Jones LP, et al. Respiratory Syncytial Virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J. Immunol. 2006;176(3):1600–1608.
   PubMed Web of Science ®Google Scholar
• Johnson SM, McNally BA, Ioannidis I, et al. Respiratory Syncytial Virus uses CX3CR1 as a receptor on primary human airway epithelial cultures. PLoS Pathog. 2015;11(12):e1005318.
   Web of Science ®Google Scholar
• Bakre AA, Harcourt JL, Haynes LM, et al. The central conserved region (CCR) of respiratory syncytial virus (RSV) G protein modulates host miRNA expression and alters the cellular response to infection. Vaccines (Basel). 2017;5(3):16.
   PubMed Web of Science ®Google Scholar
• Karron RA, Buonagurio DA, Georgiu AF, et al. Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc. Natl. Acad. Sci. U. S. A. 1997;94(25):13961–13966.
   PubMed Web of Science ®Google Scholar
• Bawage SS, Tiwari PM, Pillai S, et al. Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus. Adv Virol. 2013. DOI:10.1155/2013/595768.
   PubMedGoogle Scholar
• Sun Z, Pan Y, Jiang S, et al. Respiratory syncytial virus entry inhibitors targeting the F protein. Viruses. 2013;5(1):211–225.
   PubMed Web of Science ®Google Scholar
• Tayyari F, Marchant D, Moraes TJ, et al. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat. Med. 2011;17(9):1132–1135.
   PubMed Web of Science ®Google Scholar
• Triantafilou K, Kar S, Vakakis E, et al. Human respiratory syncytial virus viroporin SH: A viral recognition pathway used by the host to signal inflammasome activation. Thorax. 2013;68(1):66–75.
   PubMed Web of Science ®Google Scholar
• Gálvez NMS, Soto JA, Kalergis AM. New insights contributing to the development of effective vaccines and therapies to reduce the pathology caused by hRSV. Int J Mol Sci. 2017;18(8):1753.
   PubMed Web of Science ®Google Scholar
• Lo MS, Brazas RM, Holtzman MJ. Respiratory Syncytial Virus nonstructural proteins NS1 and NS2 mediate inhibition of stat2 expression and alpha/beta interferon responsiveness. J. Virol. 2005;79(14):9315–9319.
   PubMed Web of Science ®Google Scholar
• Shi T, Denouel A, Tietjen AK, et al. Global disease burden estimates of Respiratory Syncytial Virus–associated acute respiratory infection in older adults in 2015: A systematic review and meta-analysis. J Infect Dis. 2019 Mar. DOI:10.1093/infdis/jiz059.
   Web of Science ®Google Scholar
• Wennergren G, Kristjánsson S. Relationship between respiratory syncytial virus bronchiolitis and future obstructive airway diseases. Eur. Respir. J. 2001;18(6):1044–1058.
   PubMed Web of Science ®Google Scholar
• Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults.. Clin Microbiol Rev. 2000;13(3):371–384.
   PubMed Web of Science ®Google Scholar
• Shi T, Balsells E, Wastnedge E, et al. Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: systematic review and meta–analysis. J Glob Health. 2015. DOI:10.7189/jogh.05.020416.
   Web of Science ®Google Scholar
• Sommer C. Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol J. 2012. DOI:10.2174/1874285801105010144
   Google Scholar
• Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J. Infect. Dis. 2004;190(2):373–378.
   PubMed Web of Science ®Google Scholar
• Lambert L, Sagfors AM, Openshaw PJM, et al. Immunity to RSV in early-life. Front Immunol. 2014 Sep;5. DOI:10.3389/fimmu.2014.00466.
   PubMed Web of Science ®Google Scholar
• Young S, O’Keeffe PT, Arnott J, et al. Lung function, airway responsiveness, and respiratory symptoms before and after bronchiolitis. Arch. Dis. Child. 1995;72(1):16–24.
   PubMed Web of Science ®Google Scholar
• Zomer-Kooijker K, Uiterwaal CSPM, Van Der Gugten AC, et al. Decreased lung function precedes severe respiratory syncytial virus infection and post-respiratory syncytial virus wheeze in term infants. Eur. Respir. J. 2014;44(3):666–674.
   PubMed Web of Science ®Google Scholar
• Gomez CR, Nomellini V, Faunce DE, et al. Innate immunity and aging. Exp Gerontol. 2008;43(8):718–728.
   PubMed Web of Science ®Google Scholar
• Cusi MG, Martorelli B, Di Genova G, et al. Age related changes in T cell mediated immune response and effector memory to Respiratory Syncytial Virus (RSV) in healthy subjects. Immun Ageing. 2010;7(1). DOI:10.1186/1742-4933-7-14
   PubMedGoogle Scholar
• Falsey AR, Hennessey PA, Formica MA, et al. Respiratory Syncytial Virus infection in elderly and high-risk adults. N. Engl. J. Med. 2005;352(17):1749–1759.
   PubMed Web of Science ®Google Scholar
• Eisenhut M. Extrapulmonary manifestations of severe respiratory syncytial virus infection–a systematic review.. Crit Care. 2006. DOI:10.1186/cc4984
   Web of Science ®Google Scholar
• Kho N, Kerrigan JF, Tong T, et al. Respiratory syncytial virus infection and neurologic abnormalities: retrospective cohort study. J. Child Neurol. 2004;19(11):859–864.
   PubMed Web of Science ®Google Scholar
• Kawashima H, Ioi H, Ushio M, et al. Cerebrospinal fluid analysis in children with seizures from respiratory syncytial virus infection. Scand J Infect Dis. 2009 Jan;41(3):228–231.
   PubMed Web of Science ®Google Scholar
• Morichi S, Kawashima H, Ioi H, et al. Classification of acute encephalopathy in respiratory syncytial virus infection. J Infect Chemother. 2011 Jan;17(6):776–781.
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Fujisawa M, Tsuboi T, et al. Systemic inflammatory response syndrome and prolonged hypoperfusion lesions in an infant with respiratory syncytial virus encephalopathy. J Infect Chemother. 2013 Jan;19(5):978–982.
   PubMed Web of Science ®Google Scholar
• Kawashima H, Kashiwagi Y, Ioi H, et al. Production of chemokines in respiratory syncytial virus infection with central nervous system manifestations. J. Infect. Chemother. 2012;18(6):827–831.
   PubMed Web of Science ®Google Scholar
• Bohmwald K, Gálvez NMS, Ríos M, et al. Neurologic alterations due to respiratory virus infections. Front Cell Neurosci. 2018;12. DOI:10.3389/fncel.2018.00386.
   PubMed Web of Science ®Google Scholar
• Morichi S, Morishita N, Ishida Y, et al. Examination of neurological prognostic markers in patients with respiratory syncytial virus-associated encephalopathy. Int. J. Neurosci. 2017;127(1):44–50.
   PubMed Web of Science ®Google Scholar
• Morichi S, Kawashima H, Ioi H, et al. Cerebrospinal fluid NOx (nitrite/nitrate) in RSV-infected children with CNS symptoms. J Infect. 2009 Oct;59(4):299–301.
   PubMed Web of Science ®Google Scholar
• Li X, Fu ZF, Alvarez R, et al. Respiratory syncytial virus (RSV) infects neuronal cells and processes that innervate the lung by a process involving RSV G protein.. J Virol. 2006;80(1):537–540.
   PubMed Web of Science ®Google Scholar
• Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The respiratory syncytial virus immune globulin study group. N Engl.J Med. 1993;329(21):1524–1530.
   PubMed Web of Science ®Google Scholar
• Committee on Fetus and Newborn. Respiratory syncytial virus immune globulin intravenous: indications for Use. Pediatrics. 2004;99(4): 645–650.
   Google Scholar
• Respiratory Syncytial Virus (RSV) PREVENT study group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT study group.. Pediatrics. 1997;99(1):93–99.
   PubMed Web of Science ®Google Scholar
• Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus.. J. Infect. Dis. 1997;176(5):1215–1224.
   PubMed Web of Science ®Google Scholar
• Sáez-Llorens X, Castaño E, Null D, et al. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr. Infect. Dis. J. 1998;17(9):787–791.
   PubMed Web of Science ®Google Scholar
• DeVincenzo JP, Malley R, Ramilo O, et al. Viral concentration in upper and lower respiratory secretions from respiratory syncytial virus (RSV) infected children treated with RSV monoclonal antibody (MEDI-493) † 830. Pediatr Res. 2007. DOI:10.1203/00006450-199804001-00851.
   Google Scholar
• Village EG. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102(3):531–537.
   Web of Science ®Google Scholar
• Torchin H, Rousseau J, Marchand-Martin L, et al. Palivizumab administration in preterm infants in France: EPIPAGE-2 cohort study. Arch. Pediatr. 2018;25(2):89–94.
   PubMed Web of Science ®Google Scholar
• Subramanian KNS, Weisman LE, Rhodes T, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. 1998. DOI:10.1097/00006454-199802000-00006.
   PubMed Web of Science ®Google Scholar
• Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol.. 2007;368(3):652–665.
   PubMed Web of Science ®Google Scholar
• Wu H, Pfarr DS, Losonsky GA, et al. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol. 2008. DOI:10.1007/978-3-540-72146-8_4.
   PubMed Web of Science ®Google Scholar
• Mejías A, Chávez-Bueno S, Ríos AM, et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus Potency. Antimicrob. Agents Chemother.. 2005;49(11):4700–4707.
   PubMed Web of Science ®Google Scholar
• Fernández P, Trenholme A, Abarca K, et al. A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season. BMC Pediatr.ics. 2010;10(1). DOI:10.1186/1471-2431-10-38
   Google Scholar
• Carbonell-Estrany X, Simões EA, Dagan R, et al. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.. Pediatrics. 2010;125(1):e35–e51.
   PubMed Web of Science ®Google Scholar
• Boyoglu-Barnum S, Todd SO, Chirkova T, et al. An anti-G protein monoclonal antibody treats RSV disease more effectively than an anti-F monoclonal antibody in BALB/c mice. Virology. 2015;483:117–125.
   PubMed Web of Science ®Google Scholar
• Tripp RA, Power UF, Openshaw PJM, et al. Respiratory syncytial virus: targeting the g protein provides a new approach for an old problem. J. Virol.. 2017;92(3). DOI:10.1128/jvi.01302-17
   Web of Science ®Google Scholar
• Eiland LS. Respiratory syncytial virus: diagnosis, treatment and prevention.. J Pediatr Pharmacol Ther. 2009. DOI:10.5863/1551-6776-14.2.75
   PubMedGoogle Scholar
• Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol. Rev.. 2012;64(3):450–504.
   PubMed Web of Science ®Google Scholar
• A. & I. American Academy of Allergy, Bronchodilator definition. 2019. [cited 2020 Aug 10]. Available from: https://www.aaaai.org/conditions-and-treatments/conditions-dictionary/bronchodialator.
   Google Scholar
• Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–946.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143–178.
   PubMed Web of Science ®Google Scholar
• Carande EJ, Pollard AJ, Drysdale SB. Management of respiratory syncytial virus bronchiolitis: 2015 survey of members of the European society for paediatric infectious diseases. Can. J. Infect. Dis. Med. Microbiol.. 2016;2016:1–5.
   Web of Science ®Google Scholar
• Karadag B, Ceran O, Guven G, et al. Efficacy of salbutamol and ipratropium bromide in the management of acute bronchiolitis – a clinical trial. Respiration. 2008;76(3):283–287.
   PubMed Web of Science ®Google Scholar
• Kellner JD, Ohlsson A, Gadomski AM, et al. Efficacy of bronchodilator therapy in bronchiolitis: A meta-analysis. Arch. Pediatr. Adolesc. Med.. 1996;150(11):1166.
   PubMedGoogle Scholar
• Gadomski AM, Scribani MB. Bronchodilators for bronchiolitis. Cochrane Database Syst Rev. 2014. DOI:10.1002/14651858.CD001266.pub4
   PubMed Web of Science ®Google Scholar
• Spina D, Rigby PJ, Paterson JW, et al. Autoradiographic localization of beta-adrenoceptors in asthmatic human lung. Am. Rev. Respir. Dis.. 1989;140(5):1410–1415.
   PubMed Web of Science ®Google Scholar
• Steiner RWP. Treating acute bronchiolitis associated with RSV. Am Fam Physician. 2004 Jan 15;69(2):325-330.
   Web of Science ®Google Scholar
• Flores G, Horwitz RI. Efficacy of β2-agonists in bronchiolitis: A reappraisal and meta- analysis. Pediatrics. 1997;100(2):233–239.
   PubMed Web of Science ®Google Scholar
• Barr FE, Patel NR, Newth CJL. The pharmacologic mechanism by which inhaled epinephrine reduces airway obstruction in respiratory syncytial virus-associated bronchiolitis. J. Pediatr.. 2000;136(5):699–700.
   PubMed Web of Science ®Google Scholar
• Blumenthal MN, Brody TM. Studies on the mechanism of drug-induced bronchiolar relaxation in the guinea pig. J. Allergy. 1969;44(2):63–69.
   PubMedGoogle Scholar
• Wainwright C, Altamirano L, Cheney M, et al. A multicenter, randomized, double-blind, controlled trial of nebulized epinephrine in infants with acute bronchiolitis. N. Engl. J. Med.. 2003;349(1):27–35.
   PubMed Web of Science ®Google Scholar
• Williams DM. Clinical pharmacology of corticosteroids. Respir Care. 2018;63(6):655–670.
   PubMed Web of Science ®Google Scholar
• Gupta P, Bhatia V. Corticosteroid physiology and principles of therapy. Indian J Pediatr. 2008;75(10):1039–1044.
   PubMed Web of Science ®Google Scholar
• Lee FEH, Walsh EE, Falsey AR. The effect of steroid use in hospitalized adults with respiratory syncytial virus-related illness. Chest. 2011;140(5):1155–1161.
   PubMed Web of Science ®Google Scholar
• Cade A, Eglin R, Graham M, et al. Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis. Arch. Dis. Child.. 2000;82(2):126–130.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med. 2003;139(5_Part_1):359.
   PubMed Web of Science ®Google Scholar
• Schwiebert LM, Stellato C, Schleimer RP. The epithelium as a target of glucocorticoid action in the treatment of asthma. Am J Respir Crit Care Med. 1996;154(2_pt_2):S16-S20.
   PubMed Web of Science ®Google Scholar
• Goebel J, Estrada B, Quinonez J, et al. Prednisolone plus albuterol versus albuterol alone in mild to moderate bronchiolitis. Clin. Pediatr. (Phila).. 2000;39(4):213–220.
   PubMed Web of Science ®Google Scholar
• Buckingham SC, Jafri HS, Bush AJ, et al. A randomized, double‐blind, placebo‐controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome. J. Infect. Dis.. 2002;185(9):1222–1228.
   PubMed Web of Science ®Google Scholar
• De Clercq E. Antiviral drugs: current state of the art. J. Clin. Virol.. 2001;22(1):73–89.
   PubMed Web of Science ®Google Scholar
• Jafri HS. Treatment of respiratory syncytial virus: antiviral therapies. Pediatr Infect Dis J. 2003;22(Supplement):S89-S93.
   PubMed Web of Science ®Google Scholar
• Lugo RA, Nahata MC. Pathogenesis and treatment of bronchiolitis. Clin Pharm. 1993. DOI:10.1093/ajhp/50.3.528
   PubMedGoogle Scholar
• Lugo RA, Nahata MC. Pathogenesis and treatment of bronchiolitis. Am J Health Syst Pharm. 1993 Mar;50(3):528–548.
   Google Scholar
• Guerguerian AM, Gauthier M, Lebel MH, et al. Ribavirin in ventilated respiratory syncytial virus bronchiolitis: A randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med.. 1999;160(3):829–834.
   PubMed Web of Science ®Google Scholar
• Edell D, Khoshoo V, Ross G, et al. Early ribavarin treatment of bronchiolitis: effect on long-term respiratory morbidity. Chest. 2002;122(3):935–939.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jamaluddin M, Wang S, et al. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J. Virol.. 2003;77(10):5933–5947.
   PubMed Web of Science ®Google Scholar
• Aljabr W, Touzelet O, Pollakis G, et al. Investigating the influence of ribavirin on human respiratory syncytial virus RNA synthesis by using a high-resolution transcriptome sequencing approach. J. Virol.. 2016;90(10):4876–4888.
   PubMed Web of Science ®Google Scholar
• Sidwell RW, Huffman JH, Khare GP, et al. Broad-spectrum antiviral activity of virazole: 1-β-D-ribofuranosyl-1, 2,4-triazole-3-carboxamide. Science. 1972;177(4050):705–706.
   PubMed Web of Science ®Google Scholar
• Turner TL, Kopp BT, Paul G, et al. Respiratory syncytial virus: current and emerging treatment options. Clin. Outcomes Res.. 2014;217. DOI:10.2147/ceor.s60710.
   Google Scholar
• Chiou HE, Liu CL, Buttrey MJ, et al. Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers. Chest. 2005;128(1):263–272.
   PubMed Web of Science ®Google Scholar
• Graham BS. Vaccines against respiratory syncytial virus: the time has finally come. Vaccine. 2016;34(30):3535–3541.
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol.. 1969;89(4):422–434.
   PubMed Web of Science ®Google Scholar
• Murphy BR, Walsh EE. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J. Clin. Microbiol.. 1988;26(8):1595–1597.
   PubMed Web of Science ®Google Scholar
• Russell RF, McDonald JU, Ivanova M, et al. Partial attenuation of respiratory syncytial virus with a deletion of a small hydrophobic gene is associated with elevated interleukin-1β responses.. J Virol. 2015;89(17):8974–8981.
   PubMed Web of Science ®Google Scholar
• Garg A, Spector SA. HIV Type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity. J. Infect. Dis.. 2014;209(3):441–451.
   PubMed Web of Science ®Google Scholar
• Nguyen DT, Boes J, Van Amerongen G, et al. Infection-enhancing lipopeptides do not improve intranasal immunization of cotton rats with a delta-G candidate live-attenuated human respiratory syncytial virus vaccine. Hum Vaccines Immunother. 2013. DOI:10.4161/hv.26096.
   PubMed Web of Science ®Google Scholar
• Lambert SL, Aslam S, Stillman E, et al. A novel Respiratory Syncytial Virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models. PLoS One. 2015;10(3):e0119509.
   Web of Science ®Google Scholar
• Schneider-Ohrum K, Cayatte C, Bennett AS, et al. Immunization with low doses of recombinant postfusion or prefusion respiratory syncytial virus f primes for vaccine-enhanced disease in the cotton rat model independently of the presence of a Th1-biasing (GLA-SE) or Th2-biasing (alum) adjuvant. J Virol. 2017 Apr;91(8). DOI:10.1128/JVI.02180-16.
   PubMed Web of Science ®Google Scholar
• Fuentes S, Klenow L, Golding H, et al. Preclinical evaluation of bacterially produced RSV-G protein vaccine: strong protection against RSV challenge in cotton rat model. Sci. Rep.. 2017;7(1). DOI:10.1038/srep42428
   Web of Science ®Google Scholar
• Kurt-Jones EA, Popova L, Kwinn L, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol. 2000;1(5):398–401.
   PubMed Web of Science ®Google Scholar
• Ghildyal R, Mills J, Murray M, et al. Respiratory syncytial virus matrix protein associates with nucleocapsids in infected cells. J Gen Virol. 2002;83(Pt 4):753–757.
   PubMed Web of Science ®Google Scholar
• Kim A-R, Lee D-H, Lee S-H, et al. Protection induced by virus-like particle vaccine containing tandem repeat gene of respiratory syncytial virus G protein.. PLoS One. 2018 Jan;13(1):e0191277.
   PubMed Web of Science ®Google Scholar
• Blanco JCG, Pletneva LM, McGinnes-Cullen L, et al. Efficacy of a respiratory syncytial virus vaccine candidate in a maternal immunization model. Nat Commun. 2018;9(1). DOI:10.1038/s41467-018-04216-6
   Web of Science ®Google Scholar
• Bueno SM, González PA, Cautivo KM, et al. Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proc Natl Acad Sci. 2008;105(52):20822–20827.
   PubMed Web of Science ®Google Scholar
• Cautivo KM, Bueno SM, Cortes CM, et al. Efficient lung recruitment of respiratory syncytial virus-specific Th1 cells induced by recombinant bacillus calmette-guerin promotes virus clearance and protects from infection. J Immunol. 2010;185(12):7633–7645.
   PubMed Web of Science ®Google Scholar
• Céspedes PF, Rey-Jurado E, Espinoza JA, et al. A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in mice. Vaccine. 2017;35(5):757–766.
   PubMed Web of Science ®Google Scholar
• Soto JA, Gálvez NMS, Rivera CA, et al. Recombinant BCG vaccines reduce pneumovirus-caused airway pathology by inducing protective humoral immunity. Front Immunol. 2018 Dec;9. DOI:10.3389/fimmu.2018.02875.
   Web of Science ®Google Scholar
• PATH, RSV vaccine snapshot - PATH vaccine resource library. citedAug, 2019, 2015. http://www.path.org/vaccineresources/details.php?i=1562.
   Google Scholar
• Beran J, Lickliter JD, Schwarz TF, et al. Safety and immunogenicity of 3 formulations of an investigational respiratory syncytial virus vaccine in nonpregnant women: results from 2 phase 2 trials. J Infect Dis. 1616;217. DOI:10.1093/infdis/jiy065.
   Web of Science ®Google Scholar
• ClinicalTrials.gov - A study to rank different dosages of antigen of glaxosmithkline (GSK) biologicals’ investigational respiratory syncytial virus (RSV) Vaccine (GSK3003891A), based on their immune response and safety, when administered to healthy adult .
   Google Scholar
• ClinicalTrials.gov - Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals’ Investigational RSV Vaccine (GSK3003891A), in Healthy Women.
   Google Scholar
• ClinicalTrials.gov - Safety and reactogenicity study of glaxosmithkline (GSK) biologicals’ investigational respiratory syncytial virus (RSV) vaccine (GSK3003891A) in healthy women.
   Google Scholar
• Cunningham CK, Karron R, Muresan P, et al. Live-attenuated respiratory syncytial virus vaccine with deletion of RNA synthesis regulatory protein M2-2 and cold passage mutations is overattenuated. Open Forum Infect Dis. 2019 Jun;6(6). DOI:10.1093/ofid/ofz212.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov - Evaluating the infectivity, safety and immunogenicity of a recombinant live-attenuated respiratory syncytial virus vaccine (RSV LID cp ΔM2-2) in RSV-seronegative infants 6 to 24 months of age.
   Google Scholar
• ClinicalTrials.gov - Infectivity, safety and immunogenicity of a recombinant live-attenuated respiratory syncytial virus vaccine (RSV LID cp ΔM2-2) in RSV-seronegative infants and children 6 to 24 months of age.
   Google Scholar
• Crank MC, Ruckwardt TJ, Chen M, et al. A proof of concept for structure-based vaccine design targeting RSV in humans. Science. 2019;365(6452):505–509.
   PubMed Web of Science ®Google Scholar
• Malkin E, Yogev R, Abughali N, et al. Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age.. PLoS One. 2013;8(10):e77104.
   PubMed Web of Science ®Google Scholar
• Karron RA, Wright PF, Belshe RB, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis. 2005;191(7):1093–1104.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov - Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children.
   Google Scholar
• ClinicalTrials.gov - Evaluating the safety and immune response to a single dose of a respiratory syncytial virus (RSV) vaccine in infants and children
   Google Scholar
• McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody.. Science. 2013 May;340(6136):1113–1117.
   PubMed Web of Science ®Google Scholar
• Sivapalasingam S, Caballero-Perez D, Houghton M, et al. Phase 1 study evaluating safety, tolerability, pharmacokinetics and immunogenicity of REGN2222 in healthy adults: a new human monoclonal RSV-F antibody for RSV prevention. Open Forum Infect Dis. 2015 Dec;2(suppl_1). DOI:10.1093/ofid/ofv133.628.
   Google Scholar
• Domachowske JB, Khan AA, Esser MT, et al. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion f-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr. Infect. Dis. J.. 2018;37(9):886–892.
   PubMed Web of Science ®Google Scholar
• Regeneron Pharmaceuticals, Study to evaluate the efficacy and safety of REGN2222, for the prevention of medically attended rsv (respiratory syncytial virus) infection in preterm infants: NCT02325791 ClinicalTrials.gov, 2014. [cited 2020 Aug 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT02325791?term=REGN2222&rank=1.
   Google Scholar
• Mejias A, Garcia-Maurino C, Rodriguez-Fernandez R, et al. Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection. Vaccine. 2017;35(3):496–502.
   PubMed Web of Science ®Google Scholar
• Cespedes PF, Bueno SM, Ramirez BA, et al. Surface expression of the hRSV nucleoprotein impairs immunological synapse formation with T cells. Proc Natl Acad Sci. 2014 Aug;111(31):E3214–E3223.
   PubMed Web of Science ®Google Scholar
• Gottlieb J, Zamora MR, Hodges T, et al. ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. J Heart Lung Transplant. 2016;35(2):213–221.
   PubMed Web of Science ®Google Scholar
• DeVincenzo J, Lambkin-Williams R, Wilkinson T, et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2010;107(19):8800–8805.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov - Intranasal ALN-RSV01 administered to adult volunteers experimentally inoculated with respiratory syncytial virus
   Google Scholar
• Porter D, Guo Y, Perry J, et al. 1646. combined resistance analyses from phase 2b studies of presatovir treatment in RSV-infected adults. Open Forum Infect Dis. 2018;5(suppl_1):S48–S49.
   Google Scholar
• Hayden F, Whitley R. RSV antivirals: problems and progress. J Infect Dis. 2020. DOI:10.1093/infdis/jiaa029
   Web of Science ®Google Scholar
• ClinicalTrials.gov - Presatovir in lung transplant (LT) recipients with respiratory syncytial virus (RSV) infection
   Google Scholar
• ClinicalTrials.gov - Presatovir in hematopoietic cell transplant recipients with respiratory syncytial virus infection of the upper respiratory tract
   Google Scholar
• Perron M, Stray K, Kinkade A, et al. GS-5806 inhibits a broad range of respiratory syncytial virus clinical isolates by blocking the virus-cell fusion process. Antimicrob Agents Chemother. 2016;60(3):1264–1273.
   Web of Science ®Google Scholar
• De Vincenzo JP, McClure MW, Symons JA, et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N. Engl. J. Med.. 2015;373(21):2048–2058.
   PubMed Web of Science ®Google Scholar
• DeVincenzo J, Tait D, Efthimiou J, et al. A randomized, placebo-controlled, respiratory syncytial virus human challenge study of the antiviral efficacy, safety, and pharmacokinetics of RV521, an inhibitor of the RSV-F protein. Antimicrob Agents Chemother. 2020 Jan;64(2):e01884–19.
   PubMed Web of Science ®Google Scholar
• Coakley E, Ahmad A, Larson K, et al. LB6. EDP-938, a Novel RSV N-inhibitor, administered once or twice daily was safe and demonstrated robust antiviral and clinical efficacy in a healthy volunteer challenge study. Open Forum Infect. Dis.. 2019;6(Supplement_2):S995-S995.
   Google Scholar
• Stevens M, Rusch S, DeVincenzo J, et al. Antiviral activity of oral JNJ-53718678 in healthy adult volunteers challenged with respiratory syncytial virus: a placebo-controlled study. J Infect Dis. 2018;218(5):748–756.
   PubMed Web of Science ®Google Scholar
• PATH. RSV Vaccine and mAb Snapshot - PATH. PATH Vaccine Resour. Lib. 2019.
   Google Scholar